Inhibition of Plk1 has been suggested to be more effective in tumors with high levels of Plk1 and mutated p53, thus selection of patients with these tumor characteristics may improve the clinical outcomes of Plk1 inhibitors against solid tumors [74,75]. This evidence concerns the gene PLK1 and neoplasm.